The absolute bioavailability of ustekinumab following a single subcutaneous administration was estimated to be 57.2% in patients with psoriasis.
Pärast ühekordset nahaalust manustamist oli ustekinumabi absoluutne biosaadavus psoriaasiga patsientidel hinnanguliselt 57, 2%.